Nordhealth AS (NORDH) Earnings Call Transcripts

Nordhealth AS's Latest Earnings Call - Q1 FY2026

In Q1 2026, Nordhealth AS reported revenue of EUR 13.5 million, marking a 7.9% increase year-over-year, with recurring revenue growing by 11.4% to EUR 12.3 million. The company maintained its guidance for full-year 2026, projecting recurring revenue between EUR 50 million and EUR 53 million and adjusted EBITDA minus CapEx between negative EUR 4 million and negative EUR 1 million. Key drivers included strong growth in the Veterinary and Therapy business units, particularly due to AI advancements and geographic expansion efforts.

Reported metrics

Guidance from management

Management reiterated full-year 2026 guidance for recurring revenue between EUR 50 million and EUR 53 million and adjusted EBITDA minus CapEx between negative EUR 4 million and negative EUR 1 million.

What management said

Thanks, Alex. So for Q&A, if people have questions, please feel free to add the questions in the chat. I'll wait to see if anyone has questions. No questions. Okay. No questions seem to be coming. I'll wait a couple more. Let's hope there's one question from Martin. Can you please publish gross margins for the Veterinary & Therapy businesses or any other indicators that showcase the inherent profitability of the und...

Thanks for the question, Martin. So we have shared these in the past, and it's very likely that we'll do so again in the future. So I mean, the short answer is, yes, in future quarters, we will reshare the profitability of the individual business units.

What analysts pressed on

Analysts expressed interest in the company's gross margins for the Veterinary and Therapy businesses and questioned the strategic direction and growth potential of the Therapy division, particularly in the context of AI advancements.

Main topics on the call

• Revenue Growth — Nordhealth reported a 7.9% increase in revenue to EUR 13.5 million for Q1 2026, with recurring revenue growing by 11.4%. The growth was driven by a strong performance in core Veterinary and Therapy businesses.
• AI Developments — The company emphasized its AI strategy, highlighting products like AI Scribe and AI Actions, which have improved efficiency and are expected to drive future growth. Management stated, 'AI Actions allows you to automatica...
• Geographic Expansion — Nordhealth is focusing on expanding in the U.K., U.S., and Germany. The first German customer went live recently, and the company is localizing Provet for the German market.
• Cost Management — The company reduced headcount by 2% in Q1 2026 and plans to control cost growth, allowing revenue increases to improve EBITDA minus CapEx.

Read the full Nordhealth AS transcript (Q1 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 15 Nordhealth AS earnings call transcripts on record, spanning November 25, 2022 to May 12, 2026. Based on this history, Nordhealth AS reports quarterly. The most recent call on file is dated May 12, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

NORDH

Exchange

OB

Country

NO

Sector

Health Care

Industry

Health Care Technology

Calls on record

15

First call

November 25, 2022

Most recent

May 12, 2026

Reporting cadence

quarterly